ELOCTATE: payments to doctors
Payments that named ELOCTATE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4M
- Providers
- 314
- Transactions
- 952
- Average per transaction
- $4,178
The per-transaction average — $4,178 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 314 providers the average total is $12,667, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bioverativ Therapeutics Inc. | $3,436,040 | 86.4% |
| Sanofi | $385,835 | 9.7% |
| Swedish Orphan Biovitrum AB | $97,766 | 2.5% |
| Sanofi-aventis U.S. LLC | $57,820 | 1.5% |